

COSTING GUIDELINES FOR TUBERCULOSIS INTERVENTIONS

LUCY CUNNAMA
INÉS GARCIA BAENA
GABRIELA GOMEZ
YOKO LAURENCE
CAROL LEVIN
MARIANA SIAPKA
SEDONA SWEENEY
ANNA VASSALL
EDINA SINANOVIC

COSTING GUIDELINES FOR TUBERCULOSIS INTERVENTIONS

LUCY CUNNAMA
INÉS GARCIA BAENA
GABRIELA GOMEZ
YOKO LAURENCE
CAROL LEVIN
MARIANA SIAPKA
SEDONA SWEENEY
ANNA VASSALL
EDINA SINANOVIC

Costing guidelines for tuberculosis interventions/ Lucy Cunnama, Inés Garcia Baena, Yoko Laurence, Sedona Sweeney, Anna Vassall, Edina Sinanovic et al.

ISBN 978-92-4-000009-4

© **World Health Organization 2019**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Cunnama L, Garcia Baena I, Laurence Y, Sweeney S, Vassall A, Sinanovic E et al. Costing guidelines for tuberculosis interventions. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Cover designed by Irwin Law

Copy editing by Galbraith-Emami Associates

Designed by minimum graphics

CONTENTS

| | |
|---|-----|
| Acknowledgements | v |
| Abbreviations | vii |
| SECTION A. Introduction | 1 |
| Background | 1 |
| Aim of the guidelines | 2 |
| SECTION B. Defining TB interventions | 4 |
| Standardized unit costs for TB interventions | 4 |
| SECTION C. Study objectives and set-up | 8 |
| Initial conceptualization and defining the study team | 10 |
| Study protocol formation and submission of protocol for ethical approval | 13 |
| SECTION D. Designing data collection | 18 |
| Understanding the production process | 18 |
| Costing approaches | 21 |
| The Standardized Value TB Costing Tool Suite | 28 |
| SECTION E. Data analysis, presenting results and dissemination of cost data | 31 |
| SECTION F. Appendices | 33 |
| Appendix 1. Basic concepts and terms in costing | 33 |
| Appendix 2. Specific TB interventions | 37 |
| Appendix 3. Standardized unit costs for TB interventions | 43 |
| Appendix 4. Principles and methods reporting checklist | 49 |
| Appendix 5. Amortization table | 53 |
| Appendix 6. Protocol outline | 54 |
| Appendix 7. Examples of queries and comments from ethics committees | 55 |
| Appendix 8. Value TB Costing Tool Suite | 57 |
| Appendix 9. Non-exhaustive list of unit costs per patient per output, top-down and bottom-up generated by the Data Entry Tool | 105 |
| Appendix 10. Terms of reference for the study team | 106 |
| Appendix 11. Three case studies | 114 |
| Appendix 12. Informed consent templates | 117 |
| References | 123 |

List of figures and tables

| | |
|--|----|
| Figure 1. Standard unit costs | 5 |
| Figure 2. Example of activities for national costing study (example of Value TB) | 8 |
| Figure 3. Example of timeline for national costing study (example of Value TB) | 16 |
| Figure 4. Example of a process flow diagram for smear microscopy in a laboratory | 19 |
| Figure 5. Capital and recurrent inputs | 20 |
| Figure 6. Estimating efficiency | 22 |
| Figure 7. Top-down allocation of costs within a laboratory | 24 |
| Figure 8. Post data collection activities | 31 |
| Figure 9. Intervention flow chart | 37 |
| Figure 10a. The Value TB Costing Tool Suite | 57 |
| Figure 10b. The Value TB Costing Tool Suite | 82 |
| Figure 11. Shared above service level costs | 97 |
| | |
| Table 1. Sample of annex 3 from Reference Case [5] for TB treatment | 7 |
| Table 2. Costing approaches | 25 |
| Table 3. Defining standard costs for each intervention | 41 |

ACKNOWLEDGEMENTS

These guidelines were jointly produced by a core writing team comprising the following people: Lucy Cunnama, Health Economics Unit, University of Cape Town (UCT), Cape Town, South Africa; Inés Garcia Baena, Global TB Programme, World Health Organization (WHO), Geneva, Switzerland; Gabriela Gomez, London School of Hygiene and Tropical Medicine (LSHTM), London, England; Yoko Laurence, LSHTM, London, England; Carol Levin, University of Washington, Seattle, United States of America; Mariana Siapka, LSHTM, London, England; Sedona Sweeney, LSHTM, London, England; Anna Vassall, LSHTM, London, England; and Edina Sinanovic, UCT, Cape Town, South Africa. The writing team forms part of the Global Health Cost Consortium (GHCC), which will disseminate the guidelines alongside WHO.

The core writing team would like to thank the Value TB project research groups in Ethiopia, Georgia, India, Kenya and the Philippines, who were the first users of the guidelines. Their feedback shaped the Value TB Costing Tool Suite, which is the set of costing instruments that accompanies the guidelines.

Special thanks are due to Katherine Floyd for providing inspiration to produce new guidelines on TB costing and for her support to both the GHCC and the Value TB project. Thanks are also due to the TB Modelling and Analysis Consortium (TB MAC) and the WHO Global Taskforce on TB Impact Measurement, for feedback on the reporting formats during two of their joint annual meetings, in September 2017 and September 2019.

Funding for this work was provided by the Bill and Melinda Gates Foundation (grant no. OPP1109722), through the GHCC.

ABBREVIATIONS

| | |
|----------|---|
| 3HP | three months of once-weekly isoniazid and rifapentine |
| 6H | isoniazid for six months |
| ACF | active case finding |
| ALT | alanine aminotransferase |
| ART | antiretroviral therapy |
| AST | aspartate aminotransferase (also known as SGOT) |
| BCG | Bacille Calmette-Guérin |
| BMI | body mass index |
| COPD | chronic obstructive pulmonary disease |
| CPI | consumer price index |
| CT | computed tomography |
| CXR | chest x-ray |
| DOTS | directly observed therapy, short-course |
| DR | drug-resistant |
| DS | drug-susceptible |
| DS-TB | drug sensitive tuberculosis |
| DST | drug susceptibility testing |
| ECG | electrocardiography |
| EPTB | extra-pulmonary tuberculosis |
| FLD | first-line drugs |
| FTE | full-time equivalent |
| GFATM | Global Fund to Fight AIDS, Tuberculosis and Malaria |
| GHCC | Global Health Cost Consortium |
| H | isoniazid |
| HCW | health care worker |
| HEU UCT | Health Economics Unit, University of Cape Town |
| HMIS | health management information system |
| HR | human resources |
| ICF | intensified case finding |
| IEC | information, education and communication |
| IGRA | interferon-gamma release assay |
| INH | isoniazid |
| IPD | inpatient department |
| IPT | isoniazid preventive therapy |
| KEMRI | Kenya Medical Research Institute |
| KEMRI-WT | Kenya Medical Research Institute Wellcome Trust |
| LAMP | loop-mediated isothermal amplification |
| LED | light-emitting diode |
| LF-LAM | lateral flow urine lipoarabinomannan assay |

| | |
|----------|--|
| LJ | Lowenstein-Jensen |
| LPA | line probe assay |
| LSHTM | London School of Hygiene and Tropical Medicine |
| LTBI | latent tuberculosis infection |
| M-health | mobile-health |
| MCH | maternal and child health |
| MDR | multidrug-resistant (resistant to both rifampicin and isoniazid) |
| MDR-TB | multidrug resistant tuberculosis |
| MGIT | mycobacteria Growth Indicator Tube |
| NCDs | noncommunicable diseases |
| NGOs | non-governmental organizations |
| NTLP-P | National Tuberculosis, Leprosy and Lung Disease Program |
| NTP | National Tuberculosis Programme |
| OPD | outpatient department |
| PCF | passive case finding |
| PCR-DNA | polymerase chain reaction – deoxyribonucleic acid |
| PI | principal investigator |
| PMT | payment function |
| PPD | purified protein derivative |
| PTB | pulmonary tuberculosis |
| R | rifampicin |
| RBC | red blood cell |
| RBS | random blood sugar (also known as random blood glucose) |
| S | streptomycin |
| SGOT | serum glutamic-oxaloacetic transaminase (also known as AST) |
| SGPT | serum glutamic-pyruvic transaminase (also known as ALT) |
| SLD | second-line drugs |
| TB | tuberculosis |
| TST | tuberculin skin test (also known as PPD Mantoux test) |
| UHC | Universal Health Coverage |
| UNICEF | United Nations Children's Fund |
| USD | United States dollars |
| UV | ultraviolet |
| WBC | white blood cell |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24927

